Anti-SARS-CoV-2 antibodies
Kinetics of Anti–SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection
... navirus 2 (SARS-CoV-2) is poorly un- ...to SARS-CoV-2 (specifically, IgG against nucleocapsid and spike antigens), in 83 patients on in-center hemodialysis who recovered ...
15
Compromised SARS-CoV-2-specific placental antibody transfer
... primary anti- bodies diluted in 5% bovine serum albumin (BSA) for ...secondary antibodies (1:500 in 5% BSA – Goat anti-Mouse IgG2a (A-21133), Goat anti-mouse IgG2b (A-21141), Goat ...
27
Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities
... the rapid decline of neutralizing antibodies. 76–78 We believe that clinical trials are now needed to clarify the type of patients that could benefit from these drugs and at which stage of the infection they ...
16
Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patients
... patient 3, who suffered an active viral replication until the fatal outcome of his disease, these results suggest that serological IgA antibodies are not the main drivers of disease resolution. We could also ...
18
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
... Charneau 2 , Daniel Lévy-Bruhl 1 , Sylvie van der Werf 5,15,17 & Harold Noel 1,17 Assessment of the cumulative incidence of SARS-CoV-2 infections is critical for monitoring the course and ...
8
SARS-CoV-2 viral dynamics in non-human primates
... detectable antibodies until day 7, and only 25% had detectable anti- bodies by day 14, suggesting that the humoral response played a minor role in viral ...
16
Challenges and Issues of Anti-SARS-CoV-2 Vaccines
... concerns arose about allergic reactions following administration of the Pfizer vaccine, mainly due to the lipid envelop necessary to transport the nucleic acid. Despite the media impact, the rate of anaphylaxis observed ...
12
Distinct systemic and mucosal immune responses to SARS-CoV-2
... findings, nasopharyngeal immune response should be considered as potential biomarkers for correlates of protection during SARS-CoV-2 vaccination campaigns. Multiple studies have recently described a ...
41
Evolution of viral quasispecies during SARS-CoV-2 infection
... 01292020_IS 5092 15779 8.6% 0E+00 X non coding - M c.-7T>C 01292020_NP 5099 22852 1.2% 1.372E-56 X Start lost High M c.1A>C p.Met1? 1/669 1/222 02022020_NP 5104 18922 1.7% 1.6914E-71 X syn Low M c.6A>G p.Ala2Ala ...
36
Editorial SARS-CoV-2 et COVID-19 : pas au bout des doutes, questionnements et controverses.
... Il est heu- reux de constater qu’après des balbutiements ini- tiaux, bien compréhensibles face à une maladie inédite, des progrès considérables ont été accom- plis dans la prise en char[r] ...
5
Tracing the origins of SARS-CoV-2 in coronavirus phylogenies
... of SARS-CoV-2: (i) adaptation in an animal host before zoonotic transfer, or (ii) adaptation in humans after zoonotic transfer (Latinne et ...that SARS-CoV-2 may have been ...
33
Chaos game representation dataset of SARS-CoV-2 genome
... Chaos game representation dataset of SARS-CoV-2 genome Raquel de M. Barbosa a , Marcelo A.C. Fernandes b , c , 1 , ∗ a MIT Department of Chemical Engineering, Massachusetts Institute of Technology, ...
6
Estimating the burden of SARS-CoV-2 in France
... We use a deterministic compartmental model stratified by age to describe the transmission of SARS- CoV-2 in the French population. Upon infection, susceptible individuals will enter a latent ...
44
Sensitive visualization of SARS-CoV-2 RNA with CoronaFISH
... of SARS-CoV-2 infection ...of SARS-CoV-2 ...the SARS-CoV-2 sequence allows to distinguish it from other related viruses, which can be a common problem for ...
26
PTSD as the second tsunami of the SARS-Cov-2 pandemic
... coronavirus 2 (SARS-Cov-2) on the basis of a phylogenetic ana- lysis of related coronaviruses (Jiang et ...The SARS in 2003 was very traumatizing for populations, with a poor ...
3
Cibler la protéase majeure du SARS-CoV-2 pour fabriquer un médicament efficace contre ce coronavirus
... virus, SARS-CoV-2 (severe acute respira- tory syndrome-coronavirus-2), a causé un syndrome respiratoire aigu sévère (SRAS) chez de nombreux habitants de la pro- vince du Hubei en Chine, et, à ...
4
Une course contre la montre - Création du SARS-CoV-2 en laboratoire, un mois après son émergence !
... Le SARS-CoV-2 (severe acute respiratory syn- drome-coronavirus-2), qui a émergé à la fin de l’année 2019 en République populaire de Chine, est responsable d’une crise sanitaire mondiale ...
5
Cibler la protéase majeure du SARS-CoV-2 pour fabriquer un médicament efficace contre ce coronavirus
... du SARS-CoV-2 puisqu’il s’agit d’une protéase aspartique, comme les pepsines, les cathepsines, et les rénines, qui sont présentes naturellement dans les cellules eucaryotes [17] ...
5
Etude des facteurs sociodémographiques, comportements et pratiques associés à l’infection par le SARS-CoV-2 (ComCor)
... RESUME L’étude ComCor, qui couvre à ce jour la période du 1 er octobre 2020 au 31 janvier 2021, inclut 77 208 participants avec infection aiguë par le SARS-CoV-2, hors personnels soignants (8,2% des ...
49
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
... Treatment with HCQ To assess the anti-viral efficacy of HCQ, macaques received HCQ daily by gavage for 10 or more days. A treatment regimen of 90 mg kg −1 on 1 d.p.i. (loading dose) followed by a daily maintenance ...
19